Global Sterile Injectable Drugs Market: By Molecule Type (Large Molecules, Small Molecules), Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, Peptide Antibiotics, and Others), Disease Indication (Cancer, Diabetes, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Route of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

September 2017 | 207 pages | ID: GA122EC25BAEN
Precision Business Insights (PBI)

Abstracts

Global Sterile Injectables Market Report Description:

Sterile Injectables market report gives comprehensive outlook on sterile injectable across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on sterile injectable market gives historical, current, and future market sizes (US$ Mn) of drug molecules, drug types, disease application, route of administration, end users, and geographic regions. This report studies sterile injectable market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, sterile injectable market report includes drug pipeline analysis, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed sterile injectable market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the sterile injectable market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of sterile injectable .

Sterile Injectables Market:

The sterile injectable market estimated to be valued US$ 361 Bn in 2016 and poised to grow at CAGR 7.3%. Market for sterile injectable projected to reach US$ 552 Bn by 2023.

Do the burgeoning product pipelines and drug patent expiries have positive impact on the market?

The rising shift of pharmaceutical and biotechnology firms towards the development of medications for chronic diseases such as cancer, diabetes, and cardio vascular and among others have created ample growth opportunities for players in the market. Moreover, biologic have become larger part of product pipelines of several drug developers, which could affect market growth positively over the forecast period. For instance, there are around 2,500 injectable products are in developmental stage. Moreover, rising product patent expiries of several blockbuster in recent times expected to propel market growth over the forecast period. For instance in 2015, Teva Pharmaceutical Industries Ltd. lost patent for its top selling multiple sclerosis drug Copaxone.

How operational and installation cost effects the sterile injectable market?

Several industry experts noted that the cost of establishing sterile injectable plants is significantly higher viz-a-viz non sterile manufacturing plants owing to stringent aseptic requirements and complex manufacturing process; this has led to the consolidation of the industry by backward and forward integration. Moreover, competition from low cost manufacturers, value chain integration coupled with high entry barrier for new players in sterile injectable market expect impact market growth negatively over the forecast period.

North America accounts for larger market revenue share in global sterile injectable market

North America leads the global sterile injectable market in terms of revenue in 2016. Regions such as Asia Pacific and Europe presented better growth opportunities for the market players owing to conducive business policies and increased local production generic injectable . For instance, in 2013, Mylan Inc. completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited.

COMPETITION ASSESSMENT

Key players profiles in the global sterile injectable market include:

• AbbVie Inc. (U.S)
• Amgen Inc. (U.S)
• AstraZeneca plc (U.K)
• Baxter International Inc. (U.S)
• Eli Lilly and Company (U.S)
• GILEAD SCIENCES, INC. (U.S)
• GlaxoSmithKline plc. (U.K)
• Johnson & Johnson Services, Inc. (U.S)
• Merck & Co., Inc. (U.S)
• Novo Nordisk A/S (Denmark)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S)
• F. Hoffmann-La Roche AG (Switzerland)
• Sanofi (France)

Market players are focusing on mergers and acquisitions to improve their market position in sterile injectable market. For instance, in 2016, Baxter International Inc. acquired Claris Injectables Limited, a wholly owned subsidiary of Claris Lifesciences Limited, for total consideration of approximately $625mn. In 2015 Pfizer Inc. acquired Hospira, Inc., world’s leading provider of injectable and infusion technologies.

KEY FINDINGS OF THE REPORT:

• Sterile injectable market expanding at 7.3% CAGR over 2017 to 2023 to reach market value of US$ 552 Bn by 2023
• Based on molecule type large molecules accounted for larger market share in 2016
• Oncology segment expected to be most lucrative market in global sterile injectable market
• Hospital pharmacies are prime channel for sterile drug distribution across the globe
• Players focusing on expanding geographic presence to garner market opportunities in developing economies

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Molecule Type

• Large Molecules
• Small Molecules

Drug Type

• Monoclonal Antibodies
• Cytokines
• Insulin
• Peptide Hormones
• Blood Factors
• Vaccines
• Immunoglobulins
• Peptide Antibiotics
• Others

Disease Indication

• Cancer
• Diabetes
• Cardiovascular Diseases
• Musculoskeletal
• CNS
• Infections
• Others

Route of Administration

• Intravenous (IV)
• Intramuscular (IM)
• Subcutaneous (SC)
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL STERILE INJECTABLES MARKET DYNAMICS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis

6. GLOBAL STERILE INJECTABLES MARKET ANALYSIS, BY MOLECULE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Large Molecules
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Small Molecules
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL STERILE INJECTABLES MARKET FORECAST, BY DISEASE INDICATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Cancer
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Diabetes
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Cardiovascular Diseases
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Musculoskeletal
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. CNS Disorders
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.6. Infections
  7.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.7. Others
  7.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. GLOBAL STERILE INJECTABLES MARKET FORECAST, BY ROUTE OF ADMINISTRATION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Intravenous (IV)
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Intramuscular (IM)
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Subcutaneous (SC)
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Others
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. GLOBAL STERILE INJECTABLES MARKET FORECAST, BY DISTRIBUTION CHANNEL ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Hospital Pharmacies
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Retail Pharmacies
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Online Pharmacies
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

10. STERILE INJECTABLES MARKET ANALYSIS, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. North America Sterile Injectables Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.1.1. Molecule Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.1.1. Small Molecules
    10.1.1.2. Large Molecules
  10.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.2.1. Cancer
    10.1.2.2. Diabetes
    10.1.2.3. Cardiovascular Diseases
    10.1.2.4. Musculoskeletal
    10.1.2.5. CNS
    10.1.2.6. Infections
    10.1.2.7. Others
  10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.3.1. Intravenous (IV)
    10.1.3.2. Intramuscular (IM)
    10.1.3.3. Subcutaneous (SC)
    10.1.3.4. Others
  10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.4.1. Hospital Pharmacies
    10.1.4.2. Retail Pharmacies
    10.1.4.3. Online Pharmacies
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
10.2. Europe Sterile Injectables Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.2.1. Molecule Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.1.1. Small Molecules
    10.2.1.2. Large Molecules
  10.2.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.2.1. Cancer
    10.2.2.2. Diabetes
    10.2.2.3. Cardiovascular Diseases
    10.2.2.4. Musculoskeletal
    10.2.2.5. CNS
    10.2.2.6. Infections
    10.2.2.7. Others
  10.2.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.3.1. Intravenous (IV)
    10.2.3.2. Intramuscular (IM)
    10.2.3.3. Subcutaneous (SC)
    10.2.3.4. Others
  10.2.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.4.1. Hospital Pharmacies
    10.2.4.2. Retail Pharmacies
    10.2.4.3. Online Pharmacies
  10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.2.5.1. U.K
    10.2.5.2. Germany
    10.2.5.3. France
    10.2.5.4. Italy
    10.2.5.5. Spain
    10.2.5.6. Russia
    10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Sterile Injectables Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.3.1. Molecule Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.1.1. Small Molecules
    10.3.1.2. Large Molecules
  10.3.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.2.1. Cancer
    10.3.2.2. Diabetes
    10.3.2.3. Cardiovascular Diseases
    10.3.2.4. Musculoskeletal
    10.3.2.5. CNS
    10.3.2.6. Infections
    10.3.2.7. Others
  10.3.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.3.1. Intravenous (IV)
    10.3.3.2. Intramuscular (IM)
    10.3.3.3. Subcutaneous (SC)
    10.3.3.4. Others
  10.3.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.4.1. Hospital Pharmacies
    10.3.4.2. Retail Pharmacies
    10.3.4.3. Online Pharmacies
  10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.3.5.1. Japan
    10.3.5.2. China
    10.3.5.3. India
    10.3.5.4. ASEAN
    10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Sterile Injectables Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.4.1. Molecule Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.1.1. Small Molecules
    10.4.1.2. Large Molecules
  10.4.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.2.1. Cancer
    10.4.2.2. Diabetes
    10.4.2.3. Cardiovascular Diseases
    10.4.2.4. Musculoskeletal
    10.4.2.5. CNS
    10.4.2.6. Infections
    10.4.2.7. Others
  10.4.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.3.1. Intravenous (IV)
    10.4.3.2. Intramuscular (IM)
    10.4.3.3. Subcutaneous (SC)
    10.4.3.4. Others
  10.4.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.4.1. Hospital Pharmacies
    10.4.4.2. Retail Pharmacies
    10.4.4.3. Online Pharmacies
  10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.4.5.1. Brazil
    10.4.5.2. Mexico
    10.4.5.3. Argentina
    10.4.5.4. Venezuela
    10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Sterile Injectables Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  10.5.1. Molecule Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.1.1. Small Molecules
    10.5.1.2. Large Molecules
  10.5.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.2.1. Cancer
    10.5.2.2. Diabetes
    10.5.2.3. Cardiovascular Diseases
    10.5.2.4. Musculoskeletal
    10.5.2.5. CNS
    10.5.2.6. Infections
    10.5.2.7. Others
  10.5.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.3.1. Intravenous (IV)
    10.5.3.2. Intramuscular (IM)
    10.5.3.3. Subcutaneous (SC)
    10.5.3.4. Others
  10.5.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.4.1. Hospital Pharmacies
    10.5.4.2. Retail Pharmacies
    10.5.4.3. Online Pharmacies
  10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    10.5.5.1. Gulf Cooperation Council (GCC) Countries
    10.5.5.2. Israel
    10.5.5.3. South Africa
    10.5.5.4. Rest of MEA

11. COMPETITION LANDSCAPE

11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  11.2.1. AbbVie Inc. (U.S)
  11.2.2. Amgen Inc. (U.S)
  11.2.3. AstraZeneca plc (U.K)
  11.2.4. Baxter International Inc. (U.S)
  11.2.5. Eli Lilly and Company (U.S)
  11.2.6. GILEAD SCIENCES, INC. (U.S)
  11.2.7. GlaxoSmithKline plc. (U.K)
  11.2.8. Johnson & Johnson Services, Inc. (U.S)
  11.2.9. Merck & Co., Inc. (U.S)
  11.2.10. Novo Nordisk A/S (Denmark)
  11.2.11. Novartis AG (Switzerland)
  11.2.12. Pfizer Inc. (U.S)
  11.2.13. F. Hoffmann-La Roche AG (Switzerland)
  11.2.14. Sanofi (France)